Dyne Therapeutics Inc

DYN

Company Profile

  • Business description

    Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

  • Contact

    1560 Trapelo Road
    WalthamMA02451
    USA

    T: +1 781 786-8230

    E: [email protected]

    https://www.dyne-tx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    192

Stocks News & Analysis

stocks

ASX listed tariff play

Trump’s focus on US steel production may benefit this firm.
stocks

Ask the analyst: How reliant are Guzman shares on international growth?

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks

Nvidia: Back in business in China; Raising fair value estimate

Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,890.8074.400.84%
CAC 407,788.6066.510.86%
DAX 4024,188.33178.950.75%
Dow JONES (US)44,254.78231.490.53%
FTSE 1008,966.5640.010.45%
HKSE24,498.9518.81-0.08%
NASDAQ20,730.4952.690.25%
Nikkei 22539,901.19237.790.60%
NZX 50 Index12,905.41150.821.18%
S&P 5006,263.7019.940.32%
S&P/ASX 2008,639.0077.200.90%
SSE Composite Index3,516.8313.050.37%

Market Movers